Dr. Sledge on Genomic Sequencing in Patients With Breast Cancer

George Sledge, Jr., MD
Published: Sunday, Oct 14, 2018



George Sledge, Jr., MD, professor of Medicine and chief, Division of Oncology, Stanford University, discusses the benefit to the cost of genomic sequencing decreasing overtime.

With this cost continuously dropping, for the first time oncologists are able to do comprehensive looks at mutations in human patients with cancer. By doing so, they can do a better job at tailoring therapy for those patients.


George Sledge, Jr., MD, professor of Medicine and chief, Division of Oncology, Stanford University, discusses the benefit to the cost of genomic sequencing decreasing overtime.

With this cost continuously dropping, for the first time oncologists are able to do comprehensive looks at mutations in human patients with cancer. By doing so, they can do a better job at tailoring therapy for those patients.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication
x